Keywords
Last Name

Yan Dai, PhD

TitleAssistant Professor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionHematology & Medical Oncology
Address72 E. Concord St Instructional (L)
Boston MA 02118
Phone(617) 638-5650
ORCID ORCID Icon0000-0002-6894-6930
 Research Expertise & Professional Interests
The research interest of my lab is to uncover novel molecular mechanisms regarding cancer cell growth, migration, and invasion in order to develop new strategies for cancer treatment with particular interests in the role of class III HDAC in cancer development and progression. We employ two experimental systems including cultured primary and cancer cell lines, as well as mice models integrated with a number of epigenetic, molecular, and cell biology approaches to pursue in our studies. The current project in my lab includes: 1) Studying the role of SIRT1 in prostate cancer, lung cancer and breast cancer growth, invasion and metastasis. We have established various xenografts mice models, including prostate cancer and breast cancer orthotopic xenografts mice models, experimental metastatic mice models, and subcutaneous mice models. 2) Elucidating the interaction of SIRT1 and RTK signaling pathway in tumor growth and progression. 3) Studying the transcription regulation of tumor suppressor gene expression by histone deacetylase and chromatin remodeling complex. 4) Screening and developing SIRT1 inhibitors as cancer therapeutics.

 Self-Described Keywords
  • Epigenenic regulation of gene transcription
  • Protein acetylation and deacetylation
  • Tumor invasion and metastasis
  • Orthotopic and metastatic mouse models
  • Cell senescence
  • Signal transduction
  • Prostate, lung and breast cancer
  • Sickle cell disease
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Dai Y, Sangerman J, Nouraie M, Faller AD, Oneal P, Rock A, Owoyemi O, Niu X, Nekhai S, Maharaj D, Cui S, Taylor R, Steinberg M, Perrine S. Effects of hydroxyurea on F-cells in sickle cell disease and potential impact of a second fetal globin inducer. Am J Hematol. 2017 Jan; 92(1):E10-E11. PMID: 27766663.
    View in: PubMed
  2. Cho EH, Dai Y. SIRT1 controls cell proliferation by regulating contact inhibition. Biochem Biophys Res Commun. 2016 Sep 16; 478(2):868-72. PMID: 27514448.
    View in: PubMed
  3. Boosalis MS, Sangerman JI, White GL, Wolf RF, Shen L, Dai Y, White E, Makala LH, Li B, Pace BS, Nouraie M, Faller DV, Perrine SP. Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice. PLoS One. 2015; 10(12):e0144660. PMID: 26713848.
    View in: PubMed
  4. Dai Y, Sangerman J, Luo HY, Fucharoen S, Chui DH, Faller DV, Perrine SP. Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms. Blood Cells Mol Dis. 2016 Jan; 56(1):62-9. PMID: 26603726.
    View in: PubMed
  5. Zhu L, Qi J, Chiao CY, Zhang Q, Porco JA, Faller DV, Dai Y. Identification of a novel polyprenylated acylphloroglucinol-derived SIRT1 inhibitor with cancer-specific anti-proliferative and invasion-suppressing activities. Int J Oncol. 2014 Nov; 45(5):2128-36. PMID: 25189993.
    View in: PubMed
  6. Zhu L, Chiao CY, Enzer KG, Stankiewicz AJ, Faller DV, Dai Y. SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27. Mol Cancer Res. 2015 Jan; 13(1):41-9. PMID: 25143434.
    View in: PubMed
  7. Lovaas JD, Zhu L, Chiao CY, Byles V, Faller DV, Dai Y. SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate. 2013 Apr; 73(5):522-30. PMID: 23038275.
    View in: PubMed
  8. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012 Oct 25; 31(43):4619-29. PMID: 22249256.
    View in: PubMed
  9. Moore RL, Dai Y, Faller DV. Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol. 2012 Apr; 213(1):37-48. PMID: 22159506.
    View in: PubMed
  10. Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, Faller DV, Dai Y. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci. 2010; 6(6):599-612. PMID: 20941378.
    View in: PubMed
  11. Dai Y, Ngo D, Jacob J, Forman LW, Faller DV. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis. 2008 Sep; 29(9):1725-33. PMID: 18487222.
    View in: PubMed
  12. Dai Y, Faller DV. Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics. 2008; 3:53-65. PMID: 21566744.
    View in: PubMed
  13. Dai Y, Ngo D, Forman LW, Qin DC, Jacob J, Faller DV. Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol. 2007 Aug; 21(8):1807-21. PMID: 17505061.
    View in: PubMed
  14. Ye B, Aponte M, Dai Y, Li L, Ho MC, Vitonis A, Edwards D, Huang TN, Cramer DW. Ginkgo biloba and ovarian cancer prevention: epidemiological and biological evidence. Cancer Lett. 2007 Jun 18; 251(1):43-52. PMID: 17194528.
    View in: PubMed
  15. Dai Y, Wong B, Yen YM, Oettinger MA, Kwon J, Johnson RC. Determinants of HMGB proteins required to promote RAG1/2-recombination signal sequence complex assembly and catalysis during V(D)J recombination. Mol Cell Biol. 2005 Jun; 25(11):4413-25. PMID: 15899848.
    View in: PubMed
  16. Dai Y, Kysela B, Hanakahi LA, Manolis K, Riballo E, Stumm M, Harville TO, West SC, Oettinger MA, Jeggo PA. Nonhomologous end joining and V(D)J recombination require an additional factor. Proc Natl Acad Sci U S A. 2003 Mar 4; 100(5):2462-7. PMID: 12604777.
    View in: PubMed
  17. O'Driscoll M, Cerosaletti KM, Girard PM, Dai Y, Stumm M, Kysela B, Hirsch B, Gennery A, Palmer SE, Seidel J, Gatti RA, Varon R, Oettinger MA, Neitzel H, Jeggo PA, Concannon P. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell. 2001 Dec; 8(6):1175-85. PMID: 11779494.
    View in: PubMed
  18. Riballo E, Doherty AJ, Dai Y, Stiff T, Oettinger MA, Jeggo PA, Kysela B. Cellular and biochemical impact of a mutation in DNA ligase IV conferring clinical radiosensitivity. J Biol Chem. 2001 Aug 17; 276(33):31124-32. PMID: 11349135.
    View in: PubMed
  19. Kim DR, Dai Y, Mundy CL, Yang W, Oettinger MA. Mutations of acidic residues in RAG1 define the active site of the V(D)J recombinase. Genes Dev. 1999 Dec 1; 13(23):3070-80. PMID: 10601033.
    View in: PubMed
Yan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department